Safety and efficacy of dual therapy with daclatasvir and asunaprevir for patients with chronic Hepatitis C

Safety and efficacy of dual therapy with daclatasvir and asunaprevir for patients with chronic Hepatitis C - Safety of daclatasvir and asunaprevir

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022432

Enrollment

400

Registered

2016-05-24

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: genotype 1b HCV-infected patients.

Exclusion criteria

Exclusion criteria: Patients with decompensated cirrhosis

Design outcomes

Primary

Measure	Time frame
sustained virological response (negative for serum HCV RNA at 24 weeks after the treatment)	—

Secondary

Measure	Time frame
adverse event	—

Countries

Japan

Contacts

Public ContactMichio Imamura

Applied Life Science, Institute of Biomedical & Health Science, Hiroshima University Department of Gastroenterology and Metabolism

mimamura@hiroshima-u.ac.jp082-257-5190

Outcome results